New combination approach may help crush resistance to treatment in lung cancer patients
New-generation lung cancer drugs have been effective in a large number of patients, but within about a year, the patients tend to develop resistance to the therapy. Researchers at the Weizmann Institute of Science, in collaboration with physicians, have conducted a study in mice, in which they used existing drugs in a new combination to help crush potential resistance to the treatment. Their findings were published recently in the journal Clinical Cancer Research.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063